Market Overview

Benzinga's Top Upgrades

Share:
Benzinga's Top Upgrades
Related BMY
A Surprisingly Clean, Straightforward Approval Gives Portola Pharma Shares A Shot Of Upside
Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod
Related GNRC
12 Biggest Mid-Day Losers For Wednesday
Benzinga's Top Upgrades, Downgrades For April 5, 2017

Analysts at Morgan Stanley upgraded Bristol-Myers Squibb Company (NYSE: BMY) from “equal-weight” to “overweight.” The target price for Bristol-Myers Squibb has been raised from $45 to $60. Bristol-Myers Squibb's shares closed at $48.77 on Friday.

Analysts at Goldman Sachs upgraded Generac Holdings (NYSE: GNRC) from “sell” to “neutral.” The target price for Generac Holdings has been raised from $32 to $49. Generac's shares closed at $50.44 on Friday.

Guggenheim Securities upgraded FMC Technologies (NYSE: FTI) from “neutral” to “buy.” The target price for FMC Technologies is set to $60. FMC Technologies' shares closed at $51.13 on Friday.

Analysts at Bank of America upgraded Astrazeneca PLC (NYSE: AZN) from “underperform” to “neutral.” Astrazeneca's shares closed at $52.74 on Friday.

Latest Ratings for BMY

DateFirmActionFromTo
May 2017BMO CapitalDowngradesMarket PerformUnderperform
Dec 2016JefferiesUpgradesHoldBuy
Oct 2016Hilliard LyonsUpgradesNeutralLong-Term Buy

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: top upgradesUpgrades Analyst Ratings

 

Related Articles (AZN + BMY)

View Comments and Join the Discussion!